MERION STATION, Pa.,
Nov. 4, 2015 /PRNewswire/ --
Globus Medical, Inc. (Nasdaq: GMED)
The Law Office is investigating Globus Medical, Inc.
(GMED) concerning possible violations of federal securities
laws by the Company and/or certain of its officers and directors.
According to a lawsuit filed, throughout the Class Period
(2/26/14 thru 8/5/14) defendants
issued materially false and misleading statements to investors
and/or failed to disclose that: (1) Globus Medical's relationship
with a significant distributor was deteriorating; (2) such
deterioration was negatively impacting Globus Medical's financial
performance; and (3) as a result of the foregoing, defendants'
statements about Globus Medical's business, operations, and
prospects, were false and misleading and/or lacked a reasonable
basis. When the true details entered the market, the lawsuit claims
that investors suffered damages.
If you would like to learn more about the investigation or you
wish to discuss this matter, please contact Marc S. Henzel (610) 660-8000, email at
Mhenzel@Henzellaw.com, or visit the firms website at
www.henzellaw.com.
USA Technologies, Inc. (Nasdaq: USAT)
The Law Office is investigating USA Technologies, Inc.
(USAT) concerning possible violations of federal securities
laws by the Company and/or certain of its officers and directors.
According to a lawsuit filed, during the class period
(9/29/14 thru 9/29/15) Defendants made false and/or
misleading statements and/or failed to disclose that: (1) there
were significant deficiencies in both the design and operating
effectiveness of USA Technologies'
internal control over financial reporting; (2) the combined
deficiencies represented a material weakness in internal control;
(3) due to these deficiencies, USA
Technologies' procedures failed to identify a large number of
uncollectible small balance accounts; and (4) as a result,
USA Technologies' public
statements were materially false and misleading at all relevant
times." On September 29, 2015,
USA Technologies revealed it was
unable to file its annual report for the fiscal year ended
June 30, 2015 on Form 10-K with the
SEC. On this news, shares of USA Technologies fell $0.28, or 10.1%, to close at $2.49 on September 30,
2015.
If you would like to learn more about the investigation or you
wish to discuss this matter, please contact Marc S. Henzel (610) 660-8000, email at
Mhenzel@Henzellaw.com, or visit the firms website at
www.henzellaw.com.
Constant Contact, Inc. (Nasdaq: CTCT)
The firm is investigating the fairness of the sale of Constant
Contact, Inc. (Nasdaq: CTCT) to Endurance International Group
Holdings, Inc. (EIGI). The two companies have entered into a
definitive agreement under which Endurance International will
acquire all of Constant Contact's outstanding shares of common
stock for $32.00 per share in cash,
valuing Constant Contact at approximately $1.1 billion. The value represents a multiple of
12x 2015 estimated adjusted EBITDA, including cash on its balance
sheet. Including expected synergies, this represents a multiple of
7x 2015 estimated adjusted EBITDA. The offer represents a premium
of approximately 23 percent over Constant Contact's closing price
of $26.10 on October 30, 2015.
If you would like to learn more about the investigation or you
wish to discuss this matter, please contact Marc S. Henzel (610) 660-8000, email at
Mhenzel@Henzellaw.com, or visit the firms website at
www.henzellaw.com.
Dyax Corp. (Nasdaq: DYAX)
The firm is investigating potential legal claims against the
board of directors of Dyax Corp. (Nasdaq: DYAX) regarding possible
breaches of fiduciary duties and other violations of law related to
the Company's entry into an agreement to be acquired by Shire plc
(NASDAQ: SHPG).
It was announced that Shire will acquire Dyax for $37.30 in cash per Dyax share, for aggregate
upfront consideration of approximately $5.9
billion. Dyax shareholders may receive additional value
through a non-tradable contingent value right (CVR) that will pay
$4.00 in cash per Dyax share upon
approval of DX-2930 in HAE, representing a potential additional
$646 million in aggregate contingent
consideration.
If you would like to learn more about the investigation or you
wish to discuss this matter, please contact Marc S. Henzel (610) 660-8000, email at
Mhenzel@Henzellaw.com, or visit the firms website at
www.henzellaw.com.
Hutchinson Technology (Nasdaq: HTCH)
The firm is investigating the fairness of the sale of Hutchinson
Technology (Nasdaq: HTCH) to TDK Corporation for $3.62 per share in cash and up to $0.38 cash additional consideration per
share.
The companies announced that they have entered into a definitive
merger agreement under which TDK will acquire all of the
outstanding shares of common stock of HTI for base consideration of
US$3.62 per share, plus additional
consideration of up to US$0.38 per
share, depending on the level of cash (subject to certain
adjustments) less any outstanding borrowings on HTI's revolving
line of credit ("net cash") held by HTI as of the last day of the
fiscal month immediately preceding the closing date. The amount of
additional consideration, if any, will equal approximately
US$0.01 per share for each
US$500,000 of HTI's net cash over
US$17.5 million as of the measurement
date.
If you would like to learn more about the investigation or you
wish to discuss this matter, please contact Marc S. Henzel (610) 660-8000, email at
Mhenzel@Henzellaw.com, or visit the firms website at
www.henzellaw.com.
MedAssets, Inc. (Nasdaq: MDAS)
The firm is investigation the fairness of the sale of MedAssets,
Inc. (Nasdaq: MDAS) to Pamplona Capital Management for $31.35 per share.
Pamplona Capital Management (Pamplona) announced it had agreed
to acquire MedAssets (NASDAQ:MDAS). Pamplona is purchasing
MedAssets for $31.35 per share, which
represents a total enterprise value of approximately $2.7 billion for the acquisition.
If you would like to learn more about the investigation or you
wish to discuss this matter, please contact Marc S. Henzel (610) 660-8000, email at
Mhenzel@Henzellaw.com, or visit the firms website at
www.henzellaw.com.
The Law Offices of Marc S. Henzel
is a national shareholder litigation firm representing shareholders
& investors in various areas of securities laws including but
not limited to; class actions, derivatives, transactional
(buyouts/mergers/acquisitions) and FINRA & NYSE
Arbitrations.
Attorney advertising. © 2015 Law Offices of Marc S. Henzel. The law firm responsible
for this advertisement is Marc S.
Henzel. Prior results do not guarantee or predict a
similar outcome with respect to any future matter.
Contact:
Law Offices of Marc S. Henzel
Marc S. Henzel
Email: Mhenzel@Henzellaw.com
Phone 610-660-8000
Website: www.henzellaw.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/law-offices-of-marc-s-henzel-announces-investigations-of-globus-medical-inc-usa-technologies-inc-constant-contact-inc-dyax-corp-hutchinson-technology-and-medassets-inc-300171809.html
SOURCE Law Offices of Marc S.
Henzel